Taylor & Francis becomes the newest Supporter of Open Pharma

Kim Johnson

Open Pharma and Taylor & Francis are delighted to announce that Taylor & Francis has become the latest official Supporter of the Open Pharma initiative.   

Open Pharma aims to drive positive change in the communication of research funded by the pharmaceutical industry, with workstreams focused on improving the transparency, accountability, accessibility and discoverability of published research.

Taylor & Francis is one of the world’s leading scholarly publishers and has a strong commitment to open research principles. Today’s announcement that Taylor & Francis has become an official Supporter of Open Pharma reflects the fact that the two organizations share the same commitment to connecting pharma with innovations in publishing to increase transparency and access to research outputs. These shared values were illustrated in 2021, when Open Pharma published their recommendations for plain language summaries of peer-reviewed medical journal publications in the Taylor & Francis journal Current Medical Research and Opinion (CMRO).1 One of more than 2700 peer-reviewed journals published by Taylor & Francis, Open Pharma selected CMRO because of its complete range of open access options and its commitment to publishing innovations and research in medical and scientific publishing.

As Tim Koder, one of the founders of Open Pharma, commented, “Taylor & Francis has been part of the Open Pharma story since we started in 2017, and we’ve always valued their expert contributions to our meetings, research and communication projects. We’re delighted that Taylor & Francis has now joined as an Open Pharma Supporter company, with privileged access to conversations about the future of pharma industry communications and the opportunity to help steer the project in new directions”.

Elizabeth Knowles, Global Portfolio Director for Medicine at Taylor & Francis explained, “Taylor & Francis has valued the opportunities to contribute to the development of Open Pharma since its launch, so it’s great to mark that officially today by becoming a Supporter. The open science advances championed by Open Pharma will make a significant difference to both the integrity and impact of pharmaceutical research, but these ambitions will only be fully realized with broad and coordinated effort. We therefore hope many more organizations, across publishing, medcomms, pharma and other stakeholder groups, will join us in supporting the fantastic work of Open Pharma.”.

Taylor & Francis joins a growing group of Open Pharma Members and Supporters from the publishing, medical communications  and pharmaceutical industries (AstraZeneca, Boehringer Ingelheim, Galapagos, Gilead, GSK, Janssen, Novartis, Novo Nordisk, Oxford PharmaGenesis, Pfizer, Bristol Myers Squibb, Ipsen, Roche, UCB and Wiley). The formal support of Taylor & Francis, will further enrich the breadth of stakeholder perspectives among the Open Pharma Member and Supporter group.


  1. Rosenberg A, Baróniková S, Feighery L et al. Open Pharma recommendations for plain language summaries of peer-reviewed medical journal publications. Curr Med Res Opin 2021;37:2015–6. doi: https://doi.org/10.1080/03007995.2021.1971185.

About Open Pharma

Open Pharma, a multi-sponsor collaboration facilitated by Oxford PharmaGenesis, is driving positive change in the communication of pharma-sponsored research. Open Pharma is working to improve the pharma publications model by connecting pharma with innovations in publishing to increase transparency and access to research outputs. Our four core goals are:

  • Transparency – aiming to increase access to scientific information to advance medical science and improve patient care
  • Accountability – aiming to increase accountability and transparency and reduce administrative burden
  • Accessibility – aiming for faster and wider dissemination of results, increased citations and use of results
  • Discoverability – aiming to have targeted content for each user group available for a single point

For more information contact: OxfordProject@pharmagenesis.com

About Taylor & Francis

Taylor & Francis supports diverse communities of experts, researchers and knowledge makers around the world to accelerate and maximize the impact of their work. We are a leader in our field and publish across all disciplines, with a growing portfolio of over 340 Medical journals. Our expertise, built on an academic publishing heritage of over 200 years, advances trusted knowledge that fosters human progress. 

Our 2650 people, based in a global network of offices in 17 countries, use their skills and the latest technology to curate, validate and share impactful advanced, emergent and applied knowledge. Under the Taylor & Francis, Routledge and F1000 imprints we publish 2700 journals, 8000 new books each year and partner with more than 700 scholarly societies.  

Taylor & Francis is proud to be a Global Certified Accessible™ publisher and to have achieved CarbonNeutral® certification for our operations and print publications in accordance with The CarbonNeutral Protocol. 

For more information contact: newsroom@taylorandfrancis.com

Related information:

Taylor & Francis

Online: https://taylorandfrancis.com/

LinkedIn: https://www.linkedin.com/company/taylor-&-francis-group/

Twitter: https://twitter.com/tandfonline

Open Pharma

Online: https://www.openpharma.blog/

LinkedIn: www.linkedin.com/showcase/open-pharma

Twitter: www.twitter.com/_openpharma

Figshare: openpharma.figshare.com